摘要
Inammatory bowel disease(IBD),which includes Crohn’s disease(CD)and ulcerative colitis(UC),is a chronic,progressive illness thatuctuates in severity and involves recurring periods of relapse and remission.It has emerged as a global public health challenge.Traditionally,IBD has been predominantly found in Western countries,with North America and Europe exhibiting the highest rates of prevalence and incidence.Specically,the prevalence and incidence rates for UC were 505/100,000 and 249/100,000,respectively,while for CD they were 322/100,000 and 319/100,000,respectively.[1]However,there has been a recent stabilization of IBD incidence in countries with high prevalence rates.
基金
supported by the National High-Level Hospital Clinical Research Funding(Nos.2022-PUMCH-C-018,2022-PUMCH-B-022)
CAMS Innovation Fund for Medical Sciences(No.2022-I2M-C&T-B-011)
Capital Health Research and Development of Special Foundation(No.2022-2-4014)
National Natural Science Foundation of China(No.81970495)
National Key Clinical Specialty Construction Project(No.ZK108000)
